DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Washington – - 1 Botox - 1 Lavanya Krishnan - 1 Arya Derm - 1 ” Krishnan - 1 Krishnan - 1 Allergan - 1 ” - 1
Top related locs:
New York – Colorado Florida , Illinois , Kentucky , Nebraska , New Jersey , New York , Tennessee San Francisco United States New York City Florida U.S
Top related orgs:
CNN - 1 Food and Drug Administration - 1 FDA - 1 US Centers for Disease Control - 1 CDC - 1 American Board of Cosmetic - 1 Revance Therapeutics - 1 Merz Aesthetics - 1

Search resuls for: "Revance"


4 mentions found


☆ Counterfeit Botox has been found in several states. Here’s what consumers should know.
  + stars: | 2024-04-16 | by ( Jacqueline Howard | ) edition.cnn.com   time to read: +11 min
CNN —The US Food and Drug Administration is warning that dangerous counterfeit versions of Botox have been identified in multiple states, putting the safety of consumers at risk. The incidents of counterfeit Botox being administered to consumers appear to be connected to products that have been purchased from unlicensed sources and then administered by either unlicensed or licensed providers. The counterfeit Botox products may be identified by the lot number C3709C3 found on the outer carton and vial, the FDA said. Counterfeit botox has been found in several states. Most often, when counterfeit Botox is sold, “the injector knows they’re purchasing something counterfeit,” Sung said.
Persons: Washington –, Botox, Lavanya Krishnan, Arya Derm, ” Krishnan, Krishnan, Allergan, ”, “, Jimmy Sung, you’re, can’t, ” Sung, Michael Cameron, Cameron, ” Cameron, Sung, “ I’m, I’ve, Steven Williams, ” Williams, Dr, Sanjay Gupta, Cynthia Elliott, ” Elliott Organizations: CNN, Food and Drug Administration, FDA, US Centers for Disease Control, CDC, American Board of Cosmetic, Revance Therapeutics, Merz Aesthetics, Tribeca Aesthetics, Cameron Dermatology, Mount Sinai Health, American Society of Plastic Surgeons, “, CNN Health Locations: – Colorado, Florida , Illinois , Kentucky , Nebraska , New Jersey , New York , Tennessee, San Francisco, United States, New York City, New York, Florida
☆ 'Barbie Botox' goes viral but doctors inject caution
  + stars: | 2023-09-01 | by ( Leroy Leo | ) www.reuters.com   time to read: +4 min
But since the "Barbie" movie released in July, there has been an uptick in demand for use as a cosmetic procedure. Meanwhile, Revance and Evolus Inc (EOLS.O), which make similar toxins under the brand Daxxify and Jeuveau, respectively, told Reuters that though "Barbie Botox" has picked up in recent months, they do not see the trend significantly boosting sales. However, the doctors said they were concerned about a rise in use among younger women - and six doctors warned that procedures by underqualified staff at some medispas raised the risk of complications. Doctors also stressed the risk with administration by people who may not be properly qualified, especially at medispas where there is little oversight. "The science isn't quite there yet, in order to support the clinical profile of it," said Evolus CEO David Moatazedi.
Persons: Margot Robbie, BarbieBotox, that's, Barbie, Dustin Sjuts, Scot Glasberg, Revance, Shilpi Kheterpal, Kheterpal, Doctors, Melissa Levoska, David Moatazedi, Leroy Leo, Sriraj Organizations: Therapeutics, Reuters, Plastic Surgery Foundation, U.S . Food, Drug Administration, Evolus Inc, AbbVie Inc, Cleveland Clinic, Icahn School of Medicine, Thomson Locations: New York, U.S, medispas, Mount Sinai, Bengaluru
☆ Cramer's Lightning Round: Petco, Revance and DraftKings
  + stars: | 2023-03-27 | by ( Jim Cramer | ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer's Lightning Round: Petco, Revance and DraftKings"Mad Money" host Jim Cramer weighs in on various stocks, including DraftKings, PetCo and Revance.
☆ Goldman Sachs says this biotech working on a Botox rival drug could rally nearly 30%
  + stars: | 2022-09-22 | by ( Carmen Reinicke | ) www.cnbc.com   time to read: +5 min
Revance Therapeutics , a biotechnology company working on a Botox competitor set to soon launch in the U.S. is a solid bet, according to Goldman Sachs. Even if the U.S. falls into recession in the coming months, the company is poised to outperform, according to Goldman. U.S. and global growth Given these things, Goldman Sees Daxxify garnering 21% of the U.S. cosmetic neuromodulator market by 2025 and 35% by 2030. Even if the U.S. falls into recession in the coming months, the company is poised to outperform, according to Goldman. While pricing for Revance's Botox competitor has not yet been disclosed, Goldman estimates it will have a roughly 30% premium to competitors.
0 next >>
Total: 4